Detecting tumor cells in blood samples from people with advanced soft tissue sarcoma
Develops a blood test to find tumor cells in adults with advanced soft tissue sarcoma.
Plain-language title generated from the registry record
Registry title: Improved Management of Soft Tissue Sarcomas Patients With an Optimized and Innovative Sorting Technology for Circulating Tumor Cells
Key facts
- Where
- Lyon, FranceSee the site
Where in France
- BRAHMI MehdiLyon, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Leon Berard
- Trial code
- NCT07401355
- Record updated
- 10 February 2026
- Original description
This trial is a monocentric, clinico-biological cohort study with prospective enrollment, aiming to develop a method for detecting and sorting CTCs (circulating tumour cells) from liquid biopsies (fresh blood samples) in patients with advanced or metastatic soft tissue sarcomas.This study include collection of clinical data, of tumor samples (collected during standard of care).Read full original descriptionShow less
Improved Management of Soft Tissue Sarcomas Patients With an Optimized and Innovative Sorting Technology for Circulating Tumor Cells
This trial is a monocentric, clinico-biological cohort study with prospective enrollment, aiming to develop a method for detecting and sorting CTCs (circulating tumour cells) from liquid biopsies (fresh blood samples) in patients with advanced or metastatic soft tissue sarcomas.This study include collection of clinical data, of tumor samples (collected during standard of care).
Inclusion: Male or female patients ≥ 18 years at the day of consenting; Histologically confirmed diagnosis of Soft Tissue Sarcoma (STS) excepted GIST; Metastatic disease or unresectable locally advanced malignancy for which standard therapy by anthracycline is decided; At least one measurable lesion as per RECIST version 1.1; ECOG Performance Status of 0-2; Patients must have an adequate organ and bone marrow function at baseline; Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with procedures as per protocol; Covered by a medical insurance.
Exclusion: Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results; Prior treatment with anthracycline; History of other malignancy other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of disease for at least 3 years; Metabolic syndrome; Pregnant or breast-feeding woman criteria.